-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gadobenate dimeglumine (Gd-BOPTA) is an ionic linear gadolinium chelate.
Gadobenate dimeglumine (Gd-BOPTA) is an ionic linear gadolinium chelate.
The manufacturer of Gd-BOPTA does not recommend any dose correction in the case of impaired renal or liver function.
Therefore, the purpose of our study is to correlate the relative liver enhancement in the hepatobiliary phase after Gd-BOPTA administration with the patient’s liver and kidney function and delayed acquisition.
Recently, a study published in European Radiology studied the effect of liver and kidney function on the relative enhancement of liver in MRI hepatobiliary phase after injection of Gd-BOPTA to determine whether the liver-specific contrast can be adjusted according to the patient's liver and kidney function.
In this IRB-approved retrospective cohort study, we included 326 patients who underwent Gd-BOPTA-enhanced 1.
In this IRB-approved retrospective cohort study, we included 326 patients who underwent Gd-BOPTA-enhanced 1.
Of the 326 patients, 221 received 0.
Figure 1 The correlation between the normalized relative enhancement (NRE) of the liver and total serum bilirubin levels in the two groups of patients in the hepatobiliary phase; the solid line represents group A (0.
Figure 1 The correlation between the normalized relative enhancement (NRE) of the liver and total serum bilirubin levels in the two groups of patients in the hepatobiliary phase; the solid line represents group A (0.
Figure 2 The total bilirubin value (> 1.
Figure 2 The total bilirubin value (> 1.
The degree of liver enhancement in HBP stage has nothing to do with eGFR or delay, but it is significantly reduced in patients with impaired liver function.
Original source: Original source:
Matteo Bonatti,Riccardo Valletta,Giacomo Avesani,et al.
Matteo Bonatti,Riccardo Valletta,Giacomo Avesani,et al.
Liver enhancement during hepatobiliary phase after Gd-BOPTA administration: correlation with liver and renal function.
DOI: org/10.
1007/s00330-020-07279-6">10.
1007/s00330-020-07279-6 Matteo Bonatti,Riccardo Valletta,Giacomo Avesani, .
Hepatobiliary et Al liver Enhancement Phase During After Administration of Gd-BOPTA: Correlation with liver and renal function.
DOI: org/10.
1007/s00330-020-07279-6">10.
1007 / s00330-020-07279-6org/10.
1007/s00330-020-07279-6"> 10.
1007 / s00330-020-07279-6 in this message
